ArticleAnnals of hematology2026
Risk of vaso-occlusive crisis requiring hospitalization in sickle cell disease patients in brazil: retrospective cohort study of real-world data.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sickle cell disease (SCD) is associated with several complications, high health-care-related costs and reduced life expectancy. This study addresses the high incidence of vaso-occlusive crises (VOC) in patients with SCD in Brazil, a condition that significantly impacts public health and healthcare costs. Objective: To describe clinical characteristics, healthcare resource utilization, incidence risk, and complications due to VOCs requiring hospitalization among Brazilian patients with SCD. Between January 2016 to December 2018, we included 404 SCD patients aged 5–67 years and utilized routinely collected data from four referral centers in Brazil. We characterized the cohort regarding healthcare resource utilization (disease complications, mortality, pharmacological treatments, blood transfusions, laboratory and imaging tests, emergency department visits, hospitalizations, and surgeries). Of the 404 participants, 312 (77%) were aged ≥ 18 and 228 (56%) were female. The most common genotype was HbSS (n = 289, 72%). At baseline, 66.6% used hydroxyurea; osteonecrosis was the most prevalent SCD complication (82 patients, 21%). During the 3-year follow-up, 240 (59.4%, 95% confidence interval [95% CI], 55 to 64%) of the 404 participants developed VOCs requiring hospitalization. The incidence rate was 812 events per 1000 person-years (95 CI: 758 to 869). Overall, the cohort was associated with considerable healthcare utilization regarding pharmacological treatments, blood transfusions, laboratory and imaging tests, emergency department visits, and hospitalizations. SCD continues to cause substantial morbidity and utilization of the Brazilian healthcare system. New strategies and therapies are needed to prevent VOCs and improve clinical outcomes, thereby reducing VOC-related healthcare utilization in Brazil.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.